🔍 It highlights the importance of rapidly separating pDNA isoforms for quality assessment.
⏱️ The LabChip™ assay achieves this in under two minutes.
⚙️ It streamlines workflows, enhances consistency, and facilitates cost-effective production.
✅ This technique meets regulatory standards and ensures the quality of therapeutics.
🌟 A critical advancement in biopharmaceutical processing!
Introduction:
The article discusses advancements in plasmid DNA (pDNA) analytics and quality control, emphasizing the significance of rapidly assessing pDNA purity and isoform composition, which is critical for therapeutic applications in the biopharmaceutical industry.
- Circular double-stranded plasmid DNA (pDNA) is pivotal in various therapeutic applications, necessitating rigorous quality control to ensure safety and effectiveness.
- pDNA exists in three primary isoforms: supercoiled, linear, and open circular, each with varying purity requirements depending on specific applications.
- The LabChip™ Plasmid DNA assay developed by Revvity allows for the rapid separation of pDNA isoforms within 2 minutes, providing precise purity assessments for enhanced workflow efficiency.
- This assay and its associated platforms are fully automated and compliant with 21 CFR Part 11, streamlining pDNA analytics compared to traditional methods.
- Cost efficiency and reduced reagent volume requirements in the LabChip systems further underscore their utility in advancing biopharmaceutical processes while ensuring consistent product quality.
Conclusion:
With the increasing regulatory expectations for therapeutic formulations, the LabChip Plasmid DNA assay represents a significant advancement in pDNA analytics and quality control. By offering rapid, precise results while ensuring compliance with regulatory standards, this innovation facilitates the development and commercialization of effective biopharmaceutical therapies.
